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To assess the relationship between capillary leakage and inflammatory mediators during sepsis, blood sam-
ples were taken on hospital admission, as well as 24 and 72 h later, from 52 children (median age, 3.3 years)
with severe meningococcal sepsis, of whom 38 survived and 14 died. Parameters related to cytokines (interleu-
kin 6 [IL-6] IL-8, plasma phospholipase A2, and C-reactive protein [CRP]), to neutrophil degranulation (elas-
tase and lactoferrin), to complement activation (C3a, C3b/c, C4b/c, and C3- and C4-CRP complexes), and to
complement regulation (functional and inactivated C1 inhibitor and C4BP) were determined. The degree of
capillary leakage was derived from the amount of plasma infused and the severity of disease by assessing the
pediatric risk of mortality (PRISM) score. Levels of IL-6, IL-8, C3b/c, C3-CRP complexes, and C4BP on
admission, adjusted for the duration of skin lesions, were significantly different in survivors and nonsurvivors
(C3b/c levels were on average 2.2 times higher in nonsurvivors, and C3-CRP levels were 1.9 times higher in
survivors). Mortality was independently related to the levels of C3b/c and C3-CRP complexes. In agreement
with this, levels of complement activation products correlated well with the PRISM score or capillary leakage.
Thus, these data show that complement activation in patients with severe meningococcal sepsis is associated
with a poor outcome and a more severe disease course. Further studies should reveal whether complement
activation may be a target for therapeutical intervention in this disease.
The complement system is involved in many aspects of the
inflammatory response in patients with sepsis: among other
things, it mediates chemotaxis of neutrophils and opsonization
of particles and microorganisms, stimulates the release of gran-
ules from leukocytes (WBC), induces vasodilatation, and en-
hances vascular permeability, either via its influence on the
cytokine network and coagulation system or through other
means (7). Septic shock with purpura in children is mainly
caused by meningococci. It is generally accepted that this con-
dition results from the release of large amounts of lipopoly-
saccharide (LPS) into the circulation, leading to capillary leak-
age, severe hypotension, microthrombosis, and, ultimately, to
organ failure and death (3, 15). The capillary leakage which
occurs during sepsis is considered to be induced by the release
and activation of endogenous inflammatory mediators, such as
cytokines and activated components of the complement and
contact systems. Genetic deficiencies of the complement sys-
tem, in particular those of the membrane attack complex, lead
to a higher susceptibility to and recurrent infections with Neis-
seria meningitidis (10). However, most children with severe
meningococcal disease (SMD) are complement sufficient (1,
17). Thus, excessive complement activation, and not comple-
ment deficiency, is responsible for low levels of native comple-
ment components in most patients with severe meningococcal
sepsis (2, 5, 7, 9, 12, 30). The degree of complement activation
in SMD is related to the concentration of LPS in the plasma (4,
5). Patients with mild disease (low or undetectable LPS plasma
levels) have a low degree of complement activation, whereas
patients with septic shock and purpura are characterized by
high circulating levels of LPS as well as excessive complement
activation.
This study was designed to assess the extent of complement
activation in children with septic shock with purpura and its
possible route and regulation in relation to the severity of
disease, as reflected by the degree of capillary leakage and by
circulating levels of inflammatory mediators.
(This work was presented in part at two Shock Society con-
ferences, the Fourth International Congress on the Immune
Consequences of Trauma, Shock, and Sepsis, Munich, Ger-
many, 4 to 8 March 1997 [14a], and the 20th Annual Confer-
ence on Shock, Indian Wells, Calif., 15 to 18 June 1997 [14b].)
MATERIALS AND METHODS
Study protocol. Children between 3 months and 18 years of age with septic
shock and petechiae/purpura were enrolled in this study after informed consent
was obtained from their parents or legal representatives. They were admitted to
the pediatric intensive care unit (PICU) of the Sophia Children’s Hospital
between August 1988 and December 1994. Patients were eligible for inclusion
when they met both of the following criteria: (i) the presence of petechiae/
purpura for less than 12 h and (ii) the presence of shock, defined as sustained
hypotension (i.e., systolic blood pressure of ,75 mm of Hg for children between
3 and 12 months of age, ,80 mm of Hg for children 1 to 5 years old, ,85 mm
of Hg for children 6 to 12 years old, and ,100 mm of Hg for children older than
12 years) requiring intensive care treatment, or evidence of poor end organ
perfusion. The last was defined as the presence of at least two of the following
criteria: (i) unexplained metabolic acidosis (i.e., a pH of #7.3, a base excess of
#25 mmol/liter, or plasma lactate levels of .2 mmol/liter), (ii) arterial hypoxia
(i.e., an arterial O2 tension [PaO2] of #75 mm of Hg, a PaO2/fraction of inspired
O2 [FiO2] ratio of ,250, or a transcutaneous arterial O2 percent saturation
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[SaO2] of #0.96) in patients without overt cardiopulmonary disease, (iii) acute
renal failure (i.e., diuresis of ,0.5 ml/kg of body weight/h for at least 1 h despite
acute volume supplementation or evidence of adequate intravascular volume
[defined by palpability of the liver, a cardiothoracic ratio of .0.4 on chest
radiography, and a central venous pressure of .5 mm of Hg]) without preexisting
renal disease, or (iv) sudden deterioration of the baseline mental status. The
pediatric risk of mortality (PRISM) score (24) was calculated by using the most
abnormal value of each variable recorded during the first 4 h after admission to
the PICU. The exact amount of volume supplementation (human plasma or
fresh frozen plasma) administered during the stay in the ICU to restore the
hemodynamic condition of the patient was recorded. All patients received max-
imal supportive therapy when appropriate: antibiotics, volume administration,
inotropic support, and mechanical ventilation.
The study protocol was approved by the Medical Ethics Committee of the
University Hospital Rotterdam.
Collection of blood. Arterial blood samples were collected within 2 h after
admission and after 24 and 72 h. Blood for analysis of complement parameters
was collected in vials containing 3.8% trisodium citrate, immediately chilled on
ice, and centrifuged at 4,000 3 g for 10 min. Subsequently, platelet-poor plasma
was obtained by centrifugation of the supernatant at 20,000 3 g for 30 min at 4°C.
Plasma was stored at 280°C until tests were performed.
Assays. WBC and platelet counts were determined with an automated platelet
counter (H1 system; Technicon Instruments, Salem, N.H.). Lactate was mea-
sured by enzymatic endpoint determination, and C-reactive protein (CRP) was
measured by nephelometric assay (28).
C3a levels were determined by a radioimmunoassay (RIA) as described pre-
viously (14) and were expressed as nanomolar concentrations. Levels of C3a in
healthy persons are below 5 nM. Activation of C4 was assessed with an enzyme-
linked immunosorbent assay (ELISA) as described previously (33). In brief,
monoclonal antibody (MAb) anti-C4-1, which recognizes a neoepitope on the C4
activation products C4b, C4bi, and C4c (collectively referred to as C4b/c) and not
on native C4, was used as a catching antibody (Ab). Biotinylated polyclonal
rabbit anti-human C4 Abs were used as detecting Abs. Results were expressed in
nanomolar concentrations. The activation of C3 was assessed with a similar
ELISA (33). In brief, MAb anti-C3-9, recognizing a neoepitope on C3b, C3bi,
and C3c (collectively referred to as C3b/c) was used as the catching Ab, and
biotinylated polyclonal rabbit anti-human C3c Abs were used as detecting Abs.
Results were expressed in nanomolar concentrations. Complement-CRP com-
plexes were determined by a novel method (34). In short, purified complement
complexes were quantified by differential antibody ELISAs. In these ELISAs
MAbs directed against C4d and C3d were used to capture complexes. These
antibodies capture C4b-C4bi-C4d and C3b-C3bi-C3d, respectively. CRP-comple-
ment complexes were detected by biotinylated MAbs against CRP. Results were
expressed as picomolar concentrations of complement fixed to CRP. The levels
of both types of complexes in healthy volunteers were below the limit of detec-
tion (4 pM).
Functional and proteolytically inactive C1 inhibitor (fC1-Inh and iC1-Inh,
respectively), were determined by RIAs (20). The concentrations of fC1-Inh and
iC1-Inh in normal pooled plasma were 2.5 and 0.08 mM, respectively; the levels
in the patients were expressed as percents of this plasma pool level. Type II
secretory phospholipase A2 (sPLA2) was determined by ELISA (35). sPLA2
levels in healthy volunteers are below 5 mg/liter. Lactoferrin and elastase-a1-
antitrypsin complexes were determined by RIAs (21). Interleukin 6 (IL-6) and
IL-8 were measured by ELISAs obtained from the Department of Immune
Reagents (Central Laboratory of The Netherlands Red Cross Blood Transfusion
Services, Amsterdam, The Netherlands). These ELISAs were performed accord-
ing to the manufacturer’s instructions. Normal levels are ,10 pg/ml for IL-6 and
,20 pg/ml for IL-8. C4BP (C4b binding protein) concentrations were measured
by electroimmunodiffusion. Normal levels are 68 to 140% of normal plasma pool
level.
Statistical analysis. Results are expressed as medians (and ranges) unless
otherwise specified. The Mann-Whitney U test and the Wilcoxon signed-rank
test were used to evaluate between- and within-group differences. The relation-
ships between parameters were tested by assessing Spearman’s rank correlation.
Multiple regression analysis, taking account of the duration of skin lesions, was
used to compare survivors and nonsurvivors in regard to the logarithmically
transformed levels of inflammatory parameters. Logistic regression was per-
formed to evaluate the relation of the various parameters to mortality. This
analysis proceeded in two steps. In the first step, parameters were grouped into
categories (i.e., cytokine parameters, neutrophil degranulation, complement ac-
tivation products, and complement regulation). For each category separately, the
variables most predictive of mortality were determined by using backward elim-
ination. In the second step, the variables remaining after the first step were
combined and the backward-elimination procedure was applied again. The same
procedure was used with multiple regression to assess the relation between the
various parameters and capillary leakage and lactate. Two-tailed P values of
#0.05 were considered statistically significant in each test.
RESULTS
Demographics. Fifty-two patients fulfilling the entry criteria
and admitted to the PICU were enrolled in the study. Thirty-
two were males (62%), and 20 were females (38%). The me-
dian age was 3.3 years (range, 0.4 to 17.9 years). Thirty-eight of
the 52 patients (73%) survived; of the 14 (27%) deaths, 12
were from irreversible shock and 2 were from cerebral herni-
ation. Cultures of blood, cerebrospinal fluid, or skin biopsy ma-
terials revealed N. meningitidis in 46 (89%) patients and Hae-
mophilus influenzae in 1 patient. Cultures from five patients were
sterile. Thirty-three (64%) patients needed mechanical ventila-
tion. Inotropic support was necessary for 48 (92.3%) patients.
Due to the lack of sufficient plasma, complement parameters
were not determined on admission for seven patients. Forty-
nine of the children participated in a randomized, placebo-con-
trolled trial to evaluate the efficacy of a human MAb, HA-1-A
(Centoxin; Centocor, Malvern, Pa.), in meningococcal septic
shock. On admission, HA-1-A or a placebo was administered
after blood was collected. There was no significant difference
in mortality between HA-1-A-treated and placebo-treated pa-
tients.
Differences between survivors and nonsurvivors. In Tables 1
and 2 clinical and laboratory parameters related to the severity
of disease, and to the extent of cytokine release, neutrophil de-
granulation, and complement activation, in survivors and non-
survivors are compared. As expected, clinical and biochemical
parameters related to the severity of disease were significantly
different in survivors and nonsurvivors. As for parameters re-
lated to cytokines, IL-6 and IL-8 levels were substantially ele-
vated and significantly higher in nonsurvivors than in survivors.
Levels of the two acute-phase proteins CRP and sPLA2, whose
synthesis is induced by cytokines and which therefore reflect
the release of cytokines, were elevated in both patient groups,
but in contrast to cytokines, the highest levels occurred in sur-
vivors. All patients had evidence of increased degranulation of
neutrophils: elastase levels were elevated in all patients, al-
though the difference between levels in survivors and those in
nonsurvivors did not reach statistical significance (P 5 0.08).
Also, circulating levels of lactoferrin were increased in all but
one child, and the levels in nonsurvivors were significantly higher.
As for the activation of complement, C3a and C3b/c levels
were increased in all but four of the patients, whereas C4b/c
was elevated in all but one. Levels of either complement acti-
vation product were higher in nonsurvivors. All patients had
increased levels of complement-CRP complexes (C3 and C4).
However, the levels of these complexes were lower in nonsur-
vivors and the difference between the levels of C3-CRP com-
plexes in survivors and nonsurvivors was significant. fC1-Inh
levels varied widely. In survivors, levels were decreased in
some patients whereas they were normal or elevated in others.
TABLE 1. Clinical and laboratory parameters related to severity of
disease on admission in children with septic shock and purpura
Parameter
Valuea
Survivors
(n 5 38)
Nonsurvivors
(n 5 14) Normal
PRISM 10 (1–38) 20 (8–25)b
Lactate (mmol/liter) 4.3 (1.1–15.5) 7.3 (2.9–20.0)b ,2.0
Duration of petechiae (h) 5.3 (1.0–11.5) 3.6 (0.5–8.5)b
WBC (109/liter) 13.2 (1.4–44.4) 5.8 (1.3–12.6)b 35,894
Plasma infusion (ml/kg) 65 (12–307) 120 (59–182)b
a Values are medians (range).
b P , 0.05 for the difference between groups (Mann-Whitney U test).
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In the nonsurvivors, fC1-Inh levels were decreased or normal
but never elevated. However, the differences between survivors
and nonsurvivors were not significant. Levels of iC1-Inh were
normal in nine of the patients. In the other patients, the levels,
though substantially elevated, varied widely. The difference be-
tween survivors and nonsurvivors was just short of statistical
significance (P 5 0.07).
Relation between inflammatory and clinical parameters.
Multiple regression analysis for the relation between levels of
inflammatory parameters and survival and duration of skin
lesions showed that time-adjusted concentrations of IL-6, IL-8,
C3b/c, C3-CRP complexes, C4BP, and WBC were significantly
different in survivors and nonsurvivors: IL-8 levels were on
average 11.8 times higher in nonsurvivors (P 5 0.003) and were
also negatively related to the duration of petechiae (P 5
0.005). Time-adjusted levels of C3b/c on admission were on
average 2.2 times higher (P 5 0.004) in nonsurvivors than in
survivors (Fig. 1). C3-CRP levels were on average 1.9 times
higher in survivors than in nonsurvivors (P 5 0.035) and were
not related to the duration of petechiae. Logistic regression
with backward elimination showed that mortality was indepen-
dently related to the levels of C3b/c (P 5 0.03) and C3-CRP
complexes (P 5 0.03). Figure 2 shows the dichotomous distri-
bution of these two parameters.
IL-6, IL-8, and CRP levels were closely correlated with all
parameters for the severity of disease (Table 3). This was also
observed for the complement activation products. The stron-
gest correlation appeared to be that between the levels of the
complement activation products and the PRISM score (Fig. 3)
or the total amount of plasma infused. Of the neutrophil de-
granulation products, lactoferrin correlated with four of five
severity-of-disease parameters; there was a strong correlation
between elastase and the arterial lactate levels (r 5 0.59; P ,
0.001). Multiple regression analysis of the various categories of
variables showed that the levels of C3a (P , 0.001) and C4BP
(P , 0.001) were independently related to the total amount of
plasma infused; Fig. 4 represents the relation (r 5 0.77; P ,
0.001) between the total amount of plasma infused and the
weighted sum (using the regression coefficients as the weight)
of C3a and C4BP [73 3 (log10C3a) 2 1.0 3 C4BP]. Similar
statistical analyses showed that the levels of C3a (P , 0.05),
elastase (P 5 0.007), and lactoferrin (P 5 0.001) were inde-
pendently related to the arterial lactate levels. Figure 5 repre-
sents the relation (r 5 0.78; P , 0.001) between the lactate
levels and the weighted sum of C3a, elastase, and lactoferrin
[0.142 3 (log10C3a) 1 0.280 3 (log10elastase) 1 0.257 3 (log10
lactoferrin)].
Relations among inflammatory parameters. The levels of
the complement activation products C3a and C3b/c correlated
positively with those of IL-6 and IL-8 and negatively with that
TABLE 2. Parameters related to cytokines, neutrophil degranulation, complement activation, and complement regulation
on days 0, 1, and 3 after admission in children with septic shock and purpura
Parameter
Valuea
Day 0 Day 1 Day 3
NormalSurvivors
(n 5 38)
Nonsurvivors
(n 5 14)
Survivors
(n 5 34)
Nonsurvivors
(n 5 5)
Survivors
(n 5 31)
IL-6 (ng/ml) (49)b 15.3 (0.036–1,507) 280.6 (0.087–2,002)c 0.1 (0.01–186)d 20.7 (0.7–50.0)c 0.02 (0.002–7.4)d ,0.001
IL-8 (ng/ml) (49) 1.1 (0.013–381) 8.8 (0.023–369)c 0.03 (0.001–23.7)d 0.8 (0.15–2.1)c 0.03 (0.001–0.8)d ,0.002
CRP (mg/liter) (51) 128 (34–258) 70 (38–162)c 255 (145–444)d 210 (141–378)d 152 (42–401) ,2
sPLA2 (ng/ml) (48) 131 (2–1,461) 97 (9–1,907) 167 (15–847) 102 (12–573) 18 (1–384)
d ,5
Elastase (ng/ml) (49) 512 (181–3,376) 641 (251–3,132) 317 (94–572) 410 (277–699)c 177 (67–908)d ,100
Lactoferrin (ng/ml) (49) 2,584 (124–32,285) 4,275 (1,757–31,717)c 385 (146–3,518)d 662 (307–1,896)d 206 (88–920)d ,400
C3a (nmol/liter) (46) 12 (2–52) 30 (17–58)c 12 (3–49) 20 (6–30) 5.8 (,2–67)d ,5
C3b/c (nmol/liter) (49) 199 (26–826) 478 (196–1,087)c 33 (14–604)d 67 (19–92)d 25 (9–305)d ,50
C3-CRP (pmol/liter) (31) 291 (68–695) 156 (59–286)c 425 (136–1,221)d 266 (210–426)c 374 (79–1,562)d ,4
C4b/c (nmol/liter) (49) 56 (22–1,340) 110 (33–562)c 52 (13–255) 181 (33–310) 47 (20–175) ,25
C4-CRP (pmol/l) (30) 67 (30–164) 53 (26–77) 99 (33–842)d 85 (52–106) 74 (15–341)d ,4
fC1-Inh (%) (46) 79 (43–156) 72 (34–99) 100 (38–179)d 92 (76–103) 132 (52–192)d 80–120
iC1-Inh (%) (48) 378 (53–1,141) 863 (96–2,100) 168 (56–514)d 166 (128–476) 128 (75–181)d ,160
C4BP (%) (50) 72 (33–108) 53 (24–89)c 92 (58–139)d 99 (94–107)d 113 (73–224)d 80–120
a Values are medians (range).
b Number of measurements.
c P , 0.05 for the difference between groups (Mann-Whitney U test).
d P , 0.05 for the differences within groups (Wilcoxon signed-rank test).
FIG. 1. C3b/c levels on admission versus the time between the onset of
petechiae and the moment of blood sampling in surviving (open circles) and
nonsurviving (solid circles) patients. The lines represent least-squares regression
lines of the two groups (upper line, survivors; lower line, nonsurvivors). The
angles of inclination of the regression lines do not differ significantly. Time-
adjusted C3b/c values were on average 2.2 times higher in nonsurvivors (P 5
0.004).
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of CRP (Table 4). The levels of complement-CRP complexes
showed an inverse correlation pattern: the correlation of these
markers of CRP-dependent complement activation with inter-
leukins was negative, whereas that with CRP was positive. The
levels of C4b/c, representing the activation of the classical
pathway of complement, did not correlate with that of IL-6,
IL-8, or CRP. However, these levels showed a strong correla-
tion with C3a (Fig. 6) and C3b/c levels, as well as with the levels
of C4-CRP complexes, indicating that a substantial part of the
activation of the complement system had occurred through the
classical pathway, probably via CRP. C3- and C4-CRP com-
plexes both closely correlated with IL-6 and IL-8, CRP, lacto-
ferrin, and C4BP. The fC1-Inh levels correlated with levels of
the other complement regulation protein, C4BP. The levels of
iC1-Inh correlated with levels of sPLA2. Finally, the levels of
elastase and lactoferrin correlated well with those of IL-6 and
IL-8 (Table 4).
Time course of laboratory parameters. Table 2 presents the
time course of the different inflammatory variables. Levels of
CRP and sPLA2 remained elevated until 72 h after admission
and were not different in survivors and nonsurvivors, except for
the CRP levels on admission. The levels of the complement
activation products C3a and C4b/c were still elevated at 72 h,
while those of C3b/c were already normalized at 24 h. In 50%
of the patients, C3a and C4bc were higher at 24 h than on
admission. The course of complement-CRP complexes was
remarkable in that the levels were higher in survivors and the
levels observed on days 1 and 3 were higher than those on
admission. Elastase levels decreased until 72 h after admission
but remained elevated. At 24 h, the levels were different in
survivors and nonsurvivors. At 72 h, the levels in surviving
patients were still elevated, except in two patients. The levels of
lactoferrin decreased more rapidly: at 24 h, the levels were
within the normal range in 50% of the survivors. The levels of
fC1-Inh increased gradually until 72 h after admission. At that
time 50% of the survivors had levels above the upper level of
normal. There was a more rapid decrease in levels of iC1-Inh:
at 24 h, 50% of both survivors and nonsurvivors had levels
within normal limits. C4BP levels increased gradually over
FIG. 2. C3-CRP complex levels versus C3b/c levels on admission in surviving
(open circles) and nonsurviving (solid circles) patients show a dichotomous
distribution (dotted lines represent medians). Both variables were independently
related to survival.
TABLE 3. Correlation coefficients between clinical and
inflammatory parametersa
Parameter
Correlation with:
PRISM Lact Time WBC Inf
IL-6 0.41 0.43 20.52 20.7 0.62
IL-8 0.36 0.45 20.46 20.7 0.59
CRP 20.34 20.3 0.42 0.43 20.41
sPLA2 0.36
Elastase 0.59
Lactoferrin 0.29 0.68 20.33 0.37
C3a 0.69 0.46 20.51 20.4 0.75
C3b/c 0.53 0.53 20.39 20.4 0.57
C3-CRP 0.39
C4b/c 0.46 0.33 20.29 0.38
C4-CRP
fC1-In
iC1-Inf
C4BP 20.32 0.36 20.43
a Values are Spearman rank correlation coefficients; only significant (P , 0.05)
values are presented. Lact, arterial lactate; Time, duration of petechiae; WBC,
leukocyte count; Inf, total amount of plasma infused.
FIG. 3. C3a levels on admission versus PRISM score in surviving (open
circles) and nonsurviving (solid circles) patients. The dotted line represents the
upper level of normal. The solid line represents the least-squares regression line
for all data points (r 5 0.69; P , 0.001).
FIG. 4. Total amount of plasma infused (in milliliters per kilogram of body
weight [BW]) versus the weighted sum of the initial levels of C3a and C4BP
[73.1 3 (log10C3a) 2 1.0 3 C4BP] in surviving (open circles) and nonsurviving
(solid circles) patients. The line represents the least-squares regression line for
all data points (r 5 0.77; P , 0.001).
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time, although at 72 h there was a wide range (73 to 224%) of
plasma levels.
DISCUSSION
In this study of children with septic shock and purpura a high
degree of complement activation was observed, which closely
correlated with mortality, severity of disease, and degree of
capillary leakage, as estimated by the amount of plasma in-
fused. A substantial part of this complement activation was
through the classical pathway, as can be deduced from the
close relation between C4 and C3 activation products (C4b/c
and C3a or C3b/c). This activation persisted for days, and in
some patients it even increased after admission. The comple-
ment system can be activated through the classical pathway by
antigen-antibody complexes, through the alternative pathway
by bacteria or LPS, and through the mannan binding protein
pathway. As the majority of SMD patients will probably have
low or no titers of antibodies, the prevailing view is that it is
mainly the alternative pathway that contributes to complement
activation in this disease. Recently Brandtzaeg and colleagues
measured activation products of both the alternative and the
classical pathways in 20 patients with systemic meningococcal
disease (4). Activation of C4 was not different in patients with
shock and those without shock, nor did they find a correlation
between C4 and C3 activation products. They concluded that
the classical pathway contributed only slightly to total comple-
ment activation in patients with shock. In our patients, the level
of C4b/c significantly correlated with that of C3b/c or C3a,
indicating that at least part of the C3 was activated via the
classical pathway. Since we included only patients with shock,
the difference from the results of Brandtzaeg et al. may have
been caused by the larger number of children with severe
disease in our study. Accordingly, levels of activated C3 cor-
related better with severity indices than those of activated C4
(Table 2), implying that the latter correlation may have been
missed with a smaller number of patients.
Assuming that levels of antibodies against meningococci are
low in patients with SMD, one can raise the question of which
mechanism the classical pathway was activated through. CRP
can activate the classical pathway upon binding to the phos-
pholipid phosphatidylcholine, and it has been suggested that
this may occur particularly in the presence of the enzyme
sPLA2, another acute-phase protein (11). We measured CRP-
complement complexes as indicators of CRP-mediated com-
plement activation (34) and also assessed the relationship be-
tween CRP levels and complement activation parameters to
address the question of whether CRP was involved in the
observed complement activation. CRP levels were negatively
correlated with those of the complement activation products
C3a and C3b/c, and there was a negative relation between
C3-CRP levels and survival (Fig. 2). Hence, the contribution of
CRP-mediated activation to the total complement activation
was probably minor. On the other hand, the correlation be-
tween C4b/c levels and those of C4-CRP complexes was sig-
nificant, indicating that at least a substantial part of the clas-
sical pathway activation had occurred via CRP (Table 4). CRP
levels also positively correlated with the duration of petechiae,
suggesting a shorter disease course in the patients with lower
CRP levels. CRP levels were lower in nonsurvivors than in
survivors; at 24 h the levels had further increased in both
groups, but there was no longer a difference between the
groups. Thus, very likely the difference between the CRP levels
of surviving and nonsurviving patients on admission reflected
the fact that the nonsurvivors were admitted earlier in their
disease course. Accordingly, levels of sPLA2, which increase
somewhat earlier during an acute-phase reaction (25), were
not different in survivors and nonsurvivors.
Activation of the classical pathway of the complement sys-
tem is regulated by, among other things, the plasma proteins
C1-Inh and C4BP. C1-Inh inhibits activated C1, whereas C4BP
inactivates C4b by acting as a cofactor for the cleavage of C4b
by factor I. Both C4BP and C1-Inh are acute-phase proteins,
and during severe infections their levels in plasma are in-
creased. In our patients the levels of C4BP were decreased and
were negatively correlated with outcome and severity of dis-
ease (as shown by PRISM and total plasma infused) and pos-
itively correlated with the level of C1-Inh. The decreased levels
of C4BP may be explained by leakage to the extravascular
space, suppression of its synthesis by tumor necrosis factor
alpha (23), binding to serum amyloid protein P (27), or binding
to bacterial surface proteins (18). To what extent these or
other mechanisms accounted for the decreased levels of C4BP
in our patients is difficult to say. Yet this decrease is remark-
able, considering the acute-phase behavior of C4BP, and to-
gether with the relatively low levels of C1-Inh, it may indicate
a poor inhibition of the classical pathway. Furthermore, de-
creased levels of C4BP may have implications for the coagu-
lation system: low levels of C4BP lead to relatively higher
FIG. 6. Initial C4b/c values versus C3a levels in surviving (open circles) and
nonsurviving (solid circles) patients (for all patients, r 5 0.58 and P , 0.001).
FIG. 5. Arterial lactate (in millimoles per liter) on admission versus the
weighted sum of the initial levels of C3a, elastase, and lactoferrin [0.142 3
(log10C3a) 1 0.280 3 (log10elastase) 1 0.257 3 (log10lactoferrin)] in surviving
(open circles) and nonsurviving (solid circles) patients. The line represents the
least-squares regression line for all data points (r 5 0.78; P , 0.001).
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levels of free protein S, which may be of benefit during septic
shock (16, 29).
C1-Inh is the only known inhibitor in plasma of activated C1
and is the major inhibitor of activated factor XII and kallikrein
of the contact pathway of coagulation. Inhibition of these so-
called target proteinases by C1-Inh leads to the formation of
proteinase–C1-Inh complexes. The formation of these com-
plexes is accompanied by the generation of iC1-Inh species.
These species may also result from inactivation by other en-
dogenous (e.g., neutrophilic elastase) or exogenous, i.e., bac-
terial, proteinases. C1-Inh in plasma may thus exist in three
forms: fC1-Inh, iC1-Inh, and C1-Inh complexed to a proteinase
(20). In our patients the levels of fC1-Inh were decreased or
normal, which, considering its acute-phase behavior, suggests a
relative deficiency of this inhibitor and hence a diminished
regulation of the complement and contact system, with subse-
quent release of biologically active peptides. The time course
of the levels of fC1-Inh suggested consumption of this inhibi-
tor, in particular during the early phase of the disease. High
levels of iC1-Inh have been observed in experimental septic
shock in baboons (6) as well as in patients with vascular leak-
age syndrome during IL-2 therapy (13). Our data do not allow
conclusions regarding the mechanism of the generation of iC1-
Inh in our patients.
Neutrophils have been implicated as important mediators of
vascular injury (2, 26, 31) by the release of toxic oxygen species
and lysosomal proteinases, such as elastase, upon stimulation
by a large variety of agonists. In addition, elastase may facili-
tate activation of the complement, coagulation, and fibrinolytic
systems by inactivating the major inhibitors of these cascade
systems (7, 21). The levels of elastase and lactoferrin in our
patients were similar to those found in adult patients with
sepsis (21). The levels correlated with outcome, as well as with
lactate levels (Fig. 6). Hence, activation and degranulation of
neutrophils may contribute to tissue hypoxia and capillary
leakage, for example, by plugging capillaries. Elastase and lac-
toferrin were both also correlated with complement activation
products and IL-6 and IL-8, suggesting a cooperative effect of
cytokines and complement in the process of neutrophil adher-
ence and degranulation.
The hallmark of an acute inflammatory reaction is accumu-
lation of WBC and increased permeability of vessels to mac-
romolecules, which leads to edema. The tissue edema that
results from increased capillary permeability and protein-rich
fluid leakage leads to tissue injury and finally organ dysfunction
(32). Alterations in microcirculatory permeability can occur
through a chain of events that includes disruption of the gly-
cocalix (the negatively charged surface coat of the endothelial
cells), activation of specific receptors (adhesion molecules),
generation of an intracellular signal via a second messenger
(e.g., cyclic AMP, Ca21, or protein kinase C), cytoskeletal
changes, and subsequent alteration of the geometry of the
interendothelial junctions (19, 32). During sepsis the presence
of (endo)toxins and primary mediators like tumor necrosis
factor alpha and IL-1 directly and indirectly leads to activation
of endothelial cells; induces secondary mediators like IL-2,
IL-4, IL-8, gamma interferon, histamine, and bradykinin; re-
sults in metabolism of arachidonic acid to form leukotrienes,
thromboxane, platelet-activating factor, and prostaglandins;
and induces the formation of thrombin. An activated comple-
ment cascade results in vascular abnormalities and neutrophil
activation, by which neutrophil-induced damage may occur
after degranulation, aggregation, and adherence to the endo-
thelium. Almost all of these agents have direct effects on the
vascular endothelium and cause alterations in endothelial per-
meability, though the specific mechanisms for most of them
remain to be elucidated. To prove a causal role in the patho-
genesis of capillary leakage, studies of complement inhibitors
are necessary. Initial experience with C1-Inh in capillary leak-
age syndrome induced by IL-2 (13) or following bone marrow
transplantation (22) indeed seems to support a role for com-
plement in the pathogenesis of this syndrome. Individuals with
inherited component deficiencies have a markedly increased
risk of acquiring systemic meningococcal infections and may
experience recurrent episodes of these. A striking finding in
individuals with late complement component deficiencies com-
pared with normal persons is the low mortality rate associated
with meningococcal disease (8). It is therefore tempting to
speculate that complement plays a dual role in the pathogen-
esis of meningococcal sepsis: on the one hand it contributes to
the defense against meningococci; on the other hand, in pa-
tients suffering from SMD, excessive activation (in particular
via mechanisms not triggered by the microorganisms them-
TABLE 4. Relations among inflammatory mediatorsa
Parameter
Correlation with:
CRP sPLA2 Elastase Lactoferrin C3a C3b/c C3-CRP C4b/c C4-CRP fC1-In iC1-In C4BP
IL-6 20.68 0.4 0.56 0.58 0.59 20.56 20.53 20.33
IL-8 20.61 0.41 0.59 0.56 0.65 20.57 20.52 20.3
CRP 0.32 20.3 20.36 20.3 0.64 0.55 0.36
sPLA2 0.32 0.3 0.41
Elastase 0.66 0.5 0.3
Lactoferrin 0.3 0.66 0.39 0.53 20.47 20.37
C3a 20.36 20.3 0.39 0.72 0.58 0.35
C3b/c 20.3 0.5 0.53 0.72 0.5
C3-CRP 0.64 20.5 0.91 0.67
C4b/c 0.3 0.58 0.5 0.38
C4-CRP 0.55 20.4 0.91 0.38 0.6
fC1-Inf 0.52
iC1-Inf 0.4 0.39 0.32
C4BP 0.36 0.67 0.6 0.52
a Values are Spearman rank correlation coefficients; only significant (P , 0.05) values are presented.
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selves) may contribute to tissue damage and a complicated dis-
ease course.
In conclusion, excessive activation of the complement sys-
tem was demonstrated in children with septic shock and pur-
pura; the activation had occurred in part via the classical path-
way and was related to outcome, severity of disease, and extent
of capillary leakage. Further studies, for example, focusing on
the effects of the therapeutical administration of C1 esterase
inhibitor, may reveal whether this activation contributes to a
detrimental disease course.
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